Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study
BackgroundNon-B, non-C hepatocellular carcinoma (NBNC-HCC) may be related to metabolic syndrome, and the incidence of this tumor type is increasing annually. The definition of metabolic-associated fatty liver disease (MAFLD) proposed in 2020 may help to more accuratelyassess the association between...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.816472/full |
| _version_ | 1828137861663162368 |
|---|---|
| author | Yen-Po Lin Pei-Ming Wang Ching-Hui Chuang Chee-Chen Yong Yueh-Wei Liu Pao-Yuan Huang Chih-Chien Yao Ming-Chao Tsai Ming-Chao Tsai |
| author_facet | Yen-Po Lin Pei-Ming Wang Ching-Hui Chuang Chee-Chen Yong Yueh-Wei Liu Pao-Yuan Huang Chih-Chien Yao Ming-Chao Tsai Ming-Chao Tsai |
| author_sort | Yen-Po Lin |
| collection | DOAJ |
| description | BackgroundNon-B, non-C hepatocellular carcinoma (NBNC-HCC) may be related to metabolic syndrome, and the incidence of this tumor type is increasing annually. The definition of metabolic-associated fatty liver disease (MAFLD) proposed in 2020 may help to more accuratelyassess the association between metabolic syndrome and NBNC-HCC. However, this new concept has not yet been applied in NBNC-HCC research. Therefore, this study aimed to compare the clinicopathological characteristics of patients with NBNC-HCC and CHB-HCC diagnosed between 2009-13 and 2014-18, focusing on metabolic risk factors and the new concept of MAFLD.MethodPatients with BCLC-0/A-HCC who received curative hepatectomy between January 2009 and December 2018 were retrospectively assessed; the associations between clinicopathological characteristics and clinical outcomes of NBNC-HCC and CHB-HCC were analyzed by multivariate analysis.ResultCompared to patients diagnosed in 2009-13, the frequency of metabolic disorders in NBNC-HCC was significantly higher in 2014-18 [DM (p=0.049), HTN (p=0.004), BMI (p=0.017) and MAFLD (p=0.003)]; there was no significant change in patients with CHB-HCC. Moreover, CHB-HCC was an independent risk factor for HCC recurrence (HR, 1.339; 95% CI, 1.010-1.775, p=0.043) and death (HR, 1.700; 95% CI, 1.017-2.842, p=0.043) compared to NBNC-HCC.ConclusionsTherisk of MAFLD, obesity, DM, and hypertension in patients with early-stage NBNC have significantly increased in recent years, thus metabolic syndrome should be monitored in this special population. Moreover, NBNC-HCC tend to had a better prognosis than CHB-HCC, probably due to their distinct clinicopathological features. |
| first_indexed | 2024-04-11T18:26:37Z |
| format | Article |
| id | doaj.art-92454338a7304854a56ec5fac11f09a7 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T18:26:37Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-92454338a7304854a56ec5fac11f09a72022-12-22T04:09:35ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-02-011210.3389/fonc.2022.816472816472Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up StudyYen-Po Lin0Pei-Ming Wang1Ching-Hui Chuang2Chee-Chen Yong3Yueh-Wei Liu4Pao-Yuan Huang5Chih-Chien Yao6Ming-Chao Tsai7Ming-Chao Tsai8School of Medicine, Chung-Shan Medical University, Taichung, TaiwanDepartment of Family Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TaiwanDepartment of Nursing, Meiho University, Pingtung, TaiwanLiver Transplantation Center and Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanLiver Transplantation Center and Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, TaiwanBackgroundNon-B, non-C hepatocellular carcinoma (NBNC-HCC) may be related to metabolic syndrome, and the incidence of this tumor type is increasing annually. The definition of metabolic-associated fatty liver disease (MAFLD) proposed in 2020 may help to more accuratelyassess the association between metabolic syndrome and NBNC-HCC. However, this new concept has not yet been applied in NBNC-HCC research. Therefore, this study aimed to compare the clinicopathological characteristics of patients with NBNC-HCC and CHB-HCC diagnosed between 2009-13 and 2014-18, focusing on metabolic risk factors and the new concept of MAFLD.MethodPatients with BCLC-0/A-HCC who received curative hepatectomy between January 2009 and December 2018 were retrospectively assessed; the associations between clinicopathological characteristics and clinical outcomes of NBNC-HCC and CHB-HCC were analyzed by multivariate analysis.ResultCompared to patients diagnosed in 2009-13, the frequency of metabolic disorders in NBNC-HCC was significantly higher in 2014-18 [DM (p=0.049), HTN (p=0.004), BMI (p=0.017) and MAFLD (p=0.003)]; there was no significant change in patients with CHB-HCC. Moreover, CHB-HCC was an independent risk factor for HCC recurrence (HR, 1.339; 95% CI, 1.010-1.775, p=0.043) and death (HR, 1.700; 95% CI, 1.017-2.842, p=0.043) compared to NBNC-HCC.ConclusionsTherisk of MAFLD, obesity, DM, and hypertension in patients with early-stage NBNC have significantly increased in recent years, thus metabolic syndrome should be monitored in this special population. Moreover, NBNC-HCC tend to had a better prognosis than CHB-HCC, probably due to their distinct clinicopathological features.https://www.frontiersin.org/articles/10.3389/fonc.2022.816472/fullNBNCCHBhepatocellular carcinomarecurrencemetabolic associated fatty liver disease (MAFLD)metabolic dysfunction |
| spellingShingle | Yen-Po Lin Pei-Ming Wang Ching-Hui Chuang Chee-Chen Yong Yueh-Wei Liu Pao-Yuan Huang Chih-Chien Yao Ming-Chao Tsai Ming-Chao Tsai Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study Frontiers in Oncology NBNC CHB hepatocellular carcinoma recurrence metabolic associated fatty liver disease (MAFLD) metabolic dysfunction |
| title | Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study |
| title_full | Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study |
| title_fullStr | Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study |
| title_full_unstemmed | Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study |
| title_short | Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study |
| title_sort | metabolic risks are increasing in non b non c early stage hepatocellular carcinoma a 10 year follow up study |
| topic | NBNC CHB hepatocellular carcinoma recurrence metabolic associated fatty liver disease (MAFLD) metabolic dysfunction |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.816472/full |
| work_keys_str_mv | AT yenpolin metabolicrisksareincreasinginnonbnoncearlystagehepatocellularcarcinomaa10yearfollowupstudy AT peimingwang metabolicrisksareincreasinginnonbnoncearlystagehepatocellularcarcinomaa10yearfollowupstudy AT chinghuichuang metabolicrisksareincreasinginnonbnoncearlystagehepatocellularcarcinomaa10yearfollowupstudy AT cheechenyong metabolicrisksareincreasinginnonbnoncearlystagehepatocellularcarcinomaa10yearfollowupstudy AT yuehweiliu metabolicrisksareincreasinginnonbnoncearlystagehepatocellularcarcinomaa10yearfollowupstudy AT paoyuanhuang metabolicrisksareincreasinginnonbnoncearlystagehepatocellularcarcinomaa10yearfollowupstudy AT chihchienyao metabolicrisksareincreasinginnonbnoncearlystagehepatocellularcarcinomaa10yearfollowupstudy AT mingchaotsai metabolicrisksareincreasinginnonbnoncearlystagehepatocellularcarcinomaa10yearfollowupstudy AT mingchaotsai metabolicrisksareincreasinginnonbnoncearlystagehepatocellularcarcinomaa10yearfollowupstudy |